ISSN 2407-2230 | E-ISSN 1907-3062 | Universa Medicina content is searchable on DOAJ, Google Scholar, and OAI

New tuberculosis vaccine to support tuberculosis elimination

Fransisca Chondro
Submission date: Tuesday, 31 July 2018
Published date: Monday, 06 August 2018


The Sustainable Development Goals have prioritized ending the epidemic of tuberculosis by 2030.(1) Around one-third of the world population is infected with Mycobacterium tuberculosis (MTBC), but is asymptomatic, a conditon known as latent TB.According to the global tuberculosis report, in 2017 there were 5-15% of 1.7 billion  persons infected with MTBC, who will develop TB in their lives. Around 10% of latent TB will develop into active TB disease, with a higher risk in patients with immunodeficiencies such as HIV, undernutrition, diabetes mellitus, smoking, and habitual alcohol consumption. As a result there are annually an estimated 8.8 million new TB cases, with a TB mortality of 1.1 million and deaths from TB and HIV coinfection of 350 thousand cases.The World Health Organization has planned a number of strategies for TB elimination in the year 2030, such as developing rapid and accurate diagnostic tests, new regimens for the treatment of drug-susceptible or drug-resistant TB, prevention of transmission of M. tuberculosis through infection control, new vaccine candidates to prevent the development of TB, and to help improve the outcomes of treatment for TB disease.

Full Text:



World Health Organiztaion. Global tuberculosis report 2017. Geneva: World Health Organization; 2017.

Achkar JM, Casadevall A. Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 2013; 13:250-62. doi:

Fogel N. Tuberculosis: a disease without boundaries. Tuberculosis 2015;95:527-31. doi:

Coscolla M, Gagneux S. Consequences of genomic diversity in Mycobacterium tuberculosis. Seminars Immunology 2014;26:431–44. doi :

Mbugi EV, Katale BZ, Siame KK, et al. Genetic diversity of Mycobacterium tuberculosis isolated from tuberculosis patients in the Serengeti ecosystem in Tanzania. Tuberculosis. 2015;95:170-8. doi:

Cadmus S, Hill V, van Soolingen D, et al. Spoligotype profile of Mycobacterium tuberculosis complex strains from HIV-positive and -negative patients in Nigeria: a comparative analysis. J Clin Microbiol 2011;49:220-6. doi: 10.1128/JCM.01241-10.


  • There are currently no refbacks.

Copyright (c) 2018 Universa Medicina

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Creative Commons License
Universa Medicina by Faculty of Medicine, Trisakti University is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on a work at